The 2025 FPM Annual Symposium: Innovation in times of global uncertainty will explore how pharmaceutical medicine can play a vital role in addressing uncertainty and misinformation, helping bring clarity based on evidence, balance and equity.
We are continuously updating this section as we announce more speakers. Check back regularly for the latest additions to our expert speaker lineup.
Click on the following names to find out more about each speaker:
Our Deep Dive Speakers
Former Chief Medical Officer at Pfizer
Dr Freda Lewis-Hall, a pioneer in medicine and leadership, has been on the front lines of health care for more than 40 years as a clinician, researcher, and leader in the biopharmaceuticals and life sciences industries. A passionate advocate for health equity and improved outcomes for all patients, Dr Lewis-Hall has served in multiple leadership positions in the pharmaceutical industry. Most recently, she spent more than 10 years at Pfizer, Inc. on the executive leadership team as Executive Vice President, Chief Medical Officer, and later Chief Patient Officer.
Trained as a psychiatrist, Dr Lewis-Hall began her medical career in frontline patient care and became well known for her work on the impact of mental illness on families and communities and on issues of health-care disparities. She recently completed a decade of service on the inaugural Board of Governors for the Patient-Centered Outcomes Research Institute. She continues her commitment to health, science, and advocacy by serving as a board member and advisor to a number of health and life sciences organisations.
Dr Lewis-Hall is a graduate of Johns Hopkins University and Howard University College of Medicine. She is a distinguished fellow of the American Psychiatric Association and an Honorary Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom.
Non Executive Director at Compass Pathways
Dr Annalisa Jenkins FRCP is a life sciences thought leader with over 25 years of experience building and financing companies pursuing cures for the most challenging diseases globally. She has consistently mentored leadership teams advancing programs from basic research through clinical development, regulatory approval, and into healthcare systems globally.
Dr Jenkins graduated in Medicine at the University of London and received her Fellowship of the Royal College of Physicians London. She trained in Cardiovascular medicine and was a research fellow at Imperial College. Earlier in her career, Dr Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of Surgeon Lieutenant Commander. She also held senior leadership roles at Merck Serono, and Bristol Myers-Squibb over 15 years. Dr Jenkins served as President and CEO of Dimension Therapeutics, a leading gene therapy company she took public on the NASDAQ and subsequently sold to Ultragenyx.
Following her relocation back to the UK, she developed a portfolio of roles spanning the public, private and charitable sectors including Genomics England, The King’s Fund, British Heart Foundation and Chair of YouBelong, a leading mental health care charity. She is also a Board member of several growing public and private companies including AVROBIO, COMPASS Pathways, Affimed and Mereo Biopharma. Dr Jenkins serves on a number of advisory boards and contributes publicly on leadership with purpose, social entrepreneurship, diversity and innovation.
Patient Partnership Editor at the British Medical Journal
Emma Doble has lived with type 1 diabetes for over 30 years. She is the Patient Partnership Editor at the British Medical Journal (BMJ) where she leads on all of the patient partnership work across the journal and company. Emma also is the founder of CEEHealth, an organisation which guides, supports and facilitates patient partnership and involvement across healthcare.
Over the past 15 years, Emma has become an internationally recognised patient advocate for diabetes. She has worked with many organisations including the Scottish Government, World Health Organisation (WHO), Breakthrough T1D UK and Cochrane on patient partnership and co-production. In 2025, Emma won a Made with Patients award at the Patient Engagement Open Forum (PEOF) for her work in leading patient partnership at BMJ.
Chief Executive and Founding Director of the Science Media Centre
Fiona Fox is the Chief Executive and Founding Director of the Science Media Centre, which, since it was established in 2002, has become an indispensable resource for science journalists in the UK. She a has a degree in journalism and many years of experience working in media relations for high profile national organisations, including, amongst others, the Equal Opportunities Committee and the Catholic Agency for Overseas Devlopment (CAFOD).
She has received many accolades for her services to science, including an OBE, honorary fellowships of the Royal Society, the Academy of Medical Sciences, the Royal Society of Biology and the British Pharmacology Society. Fiona is also the author of ‘Beyond the Hype: Inside Science’s Biggest Media Scandals from Climategate to Covid’.
Vice President of Faculty of Pharmaceutical Medicine
Emma Harvey is an independent pharmaceutical physician with over 25 years’ experience in drug development, medical affairs and corporate leadership.
She has worked predominantly in rare and infectious diseases in both biotech and big pharma. Emma holds MRCP, is a Fellow of FPM and current Vice President of FPM.
Co-Chair of the BRIDGE Commission
Ngawai Moss works with families, researchers, clinicians and civil society organisations to ensure patient perspectives shape health research. She is a co-investigator on several studies and was recognised by Health Data Research (HDR) UK for her role in Patient and Public Involvement.
Ngawai co-chairs the Better Research, Information and Data Generation for Empowerment (BRIDGE) Commission, which focuses on improving reproductive health globally for women with chronic conditions. In 2024, she spoke at the Clinton Global Initiative during the UN General Assembly about the need for inclusive research that addresses existing data gaps. She also serves as an honorary research fellow at QMUL.
Chief Medical Advisor at PA Consulting
Hilary is a senior clinician with extensive expertise in oncology and medical management. She has served as an acute trust Medical Director and Professor of Oncology at the University of Surrey and was actively involved in clinical trials across all phases throughout her clinical career.
After more than two decades in the NHS, Hilary transitioned to the private sector, where she has spent the past 15 years in life sciences and healthcare consulting, including the last four years as Chief Medical Advisor at PA Consulting. In July 2024, she became a joint Non-Executive Director at Barking, Havering and Redbridge University Trust and Barts Health, where she chairs the Quality Assurance Committee at both organisations.
Chair of British Society of Gerontology’s Special Interest Group on Ageing Business and Society; Founder and Principal at Covostra Ltd.
Rob’s career began in the pharmaceutical industry as a field sales representative. He has since held senior roles in Government Relations and External Engagement at Pfizer, Gilead Sciences, and UCB, both in the UK and globally. In 2007, Rob founded his first healthcare communications agency and has been building Covostra since 2021, leveraging decades of experience to help pharmaceutical companies achieve distinction and leadership through strategic and impactful human-centred engagement.
Rob has extensive experience in various healthcare areas, including Oncology, Vision Care, HIV & AIDS, Immunology, Chronic Viral Hepatitis, Cardiovascular, and Rare Diseases. He is a trustee of the Primary Biliary Cholangitis Foundation and a founding member of the Leading Intestinal Failure Equality in Europe (LIFE) initiative. Rob holds a Bachelor of Laws and was awarded a Master of Public Administration from Columbia University School of International Public Affairs (SIPA).
